The Relative Strength (RS) Rating for Boston Scientific jumped into a higher percentile Friday, as it got a lift from 66 to 71.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary rating measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains tend to have an 80 or higher RS Rating as they begin their biggest runs. See if Boston Scientific can continue to rebound and clear that threshold.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock goes on to offer and clear an appropriate buy point.
EPS growth fell in the company's most recent report from 34% to 21%, but sales rose from 21% to 23%.
Boston Scientific holds the No. 5 rank among its peers in the Medical-Products industry group. Insulet is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Which Stocks Are Showing Rising Relative Strength?
